In the HOPE trial, a low-dose therapy with corticosteroids substantially reduced pain and decreased signs of inflammation in patients with painful hand osteoarthritis (OA) .
Hand OA is one of the most common OA phenotypes, and it has a high clinical burden. It leads to joint pain, disability, decreased hand strength, and reduced quality of life. The rationale of the HOPE trial has been that synovial inflammation is often present in people with hand OA and is a main determinant of both pain and disease progression, as previous data has shown. Therefore, corticosteroids might be a benefit due to their potent anti-inflammatory effect.
The HOPE trial enrolled patients with signs of synovial inflammation who met the ACR criteria for painful hand OA. Patients with ≥4 osteoarthritic nodes involving interphalangeal joints, ≥1 interphalangeal joint with soft tissue swelling or erythema, and ≥1 positive power Doppler signal or synovitis of grade 2 or highe...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Filgotinib Promising in RA Patients Naïve to Methotrexate Next Article
Psoriasis Onset Determines Sequence of Symptoms »
Table of Contents: ACR 2019
Spotlight on Rheumatoid Arthritis
What is Hot in Systemic Lupus Erythematosus
Spondyloarthritis – the Beat Goes On
Osteoarthritis – State-of-the-Art
Reproductive Issues in Rheumatic Disease
Vasculitis – Novel Treatment Modalities
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.